Related Experiment Video
Updated: Sep 16, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
[Effect of alpha-leukocyte interferon on laryngeal papillomatosis in children]
Abstract:
In 16 cases of severe juvenile laryngeal papillomatosis, alpha-leucocyte interferon was injected intramuscularly in doses of 150 000 units/kg three times a week for 6 months. Follow-up endoscopy was performed monthly to evaluate the course of the disease and to destroy all accessible papillomas by electrocoagulation, laser or forceps. Plasma interferon levels were measured monthly by the biological method in 9 of the 16 children. Recurrence of the papillomas was prevented in 11/16 cases during treatment with interferon. The effectiveness of this treatment seemed to be associated with high plasma interferon levels. The drug was perfectly tolerated in 15/16 patients. These results suggest that children with laryngeal papillomatosis would benefit from a further trial with modified and reinforced dosage.
Insights
Alpha-leucocyte interferon therapy prevented papilloma recurrence in 11 of 16 children with severe juvenile laryngeal papillomatosis. This treatment was well-tolerated and showed promising results for managing this condition.
Area of Science:
- Otolaryngology
- Virology
- Immunology
Context:
- Juvenile laryngeal papillomatosis is a rare but serious condition.
- Recurrent respiratory papillomatosis can significantly impact a child's quality of life.
- Current treatment options often involve repeated surgical interventions.
Purpose:
- To evaluate the efficacy and safety of alpha-leucocyte interferon in treating severe juvenile laryngeal papillomatosis.
- To assess the correlation between plasma interferon levels and treatment outcomes.
- To determine if interferon therapy can prevent papilloma recurrence.
Summary:
- Sixteen children with severe juvenile laryngeal papillomatosis received intramuscular alpha-leucocyte interferon (150,000 units/kg, 3x/week for 6 months).
- Papilloma recurrence was prevented in 11 out of 16 patients during the treatment period.
- Plasma interferon levels were monitored, with higher levels correlating to treatment effectiveness. The therapy was well-tolerated in 15 patients.
Impact:
- Alpha-leucocyte interferon shows potential as an effective therapeutic agent for juvenile laryngeal papillomatosis.
- The findings support further investigation into modified and higher dosage regimens.
- This approach may reduce the need for frequent surgical procedures in affected children.
More Related Videos
10:39Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
07:38Isolation of Tonsillar Mononuclear Cells to Study Ex Vivo Innate Immune Responses in a Human Mucosal Lymphoid Tissue
Published on: June 14, 2020
